New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 17, 2015
08:43 EDTBMYBristol-Myers sells Ixempra to R-PHARM, terms not disclosed
R-PHARM announces the acquisition of Ixempra from Bristol-Myers Squibb. Ixempra received marketing approval from the FDA in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement. Financial terms were not disclosed.
06:55 EDTSHPGBaxalta initiated with an Outperform at William Blair
Subscribe for More Information
06:48 EDTSHPGShire to raise Baxalta offer if given access to company's books, Telegraph says
Subscribe for More Information
06:01 EDTNVSAVEO Oncology announces license agreement with Novartis
Subscribe for More Information
August 16, 2015
15:03 EDTSHPGShire must raise bid to $35B to interest Baxalta, Sunday Times says
Shire (SHPG) will have to increase its bid for Baxalta (BXLT) by about $5B to $35B in order to entice the company's board, reports the Sunday Times, citing people working on the deal. Even a $35B deal would only be a starting point, cautioned the sources. Reference Link
August 14, 2015
17:08 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
08:36 EDTPFEPfizer's pending Hospira acquisition approved by Canadian Competition Bureau
Pfizer (PFE) announced that it received approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada. "We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira," said Ian Read, chairman and CEO of Pfizer. "We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015."
08:35 EDTPFEHayman takes Mylan, Perrigo stakes, boasts exposure to energy
Subscribe for More Information
08:26 EDTPFEPiper says Street $4B too low on Pfizer 2019 sales estimates
Piper Jaffray analyst Richard Purkiss believes the Street is underestimating Pfizer's 2019 sales by $4B. The consensus 2019 revenue estimate is $58.7B. Analysts are factoring in "overly conservative" growth assumptions for five of Pfizer's key brands, namely Prevnar, Ibrance, Xeljanz, Eliquis and Lyrica, Purkiss tells investors in a research note. Sentiment towards the stock will "improve meaningfully" as investors "wake up" to the sales turnaround from 2015, the analyst believes. Purkiss expects Pfizer's 36% discount to his $48 target price to close as sentiment improves and reiterates an Overweight rating on the pharma giant. The stock end yesterday's trading down 1c to $35.36.
07:15 EDTSHPGShire eyes more details of Baxalta sales outlook, Bloomberg reports
Subscribe for More Information
07:02 EDTNVSPrima BioMed announces commencement of milestones for IMP701 program
Subscribe for More Information
06:19 EDTGSKGlaxoSmithKline says NC plant meds safe from Legionnaires' bacteria, AP reports
GlaxoSmithKline said that the medications manufactured at its pharmaceutical plant in Zebulon, North Carolina are safe despite the company's decision to shut down the factory after the discovery of Legionnaires' bacteria, the Associated Press reports, citing an email from company spokeswoman Jenni Brewer Ligday. North Carolina health officials have said that no cases of Legionnaires' disease linked to the Glaxo plant have been reported, the report says. Reference Link
August 13, 2015
10:55 EDTMRKBMO upgrades Merck on Alzheimer's, lung cancer drug prospects
Subscribe for More Information
10:02 EDTSHPGMajor Shire holders comfortable with $50 per share Baxalta bid, Reuters says
Subscribe for More Information
10:00 EDTMRKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A. Schulman (SHLM) upgraded to Buy from Accumulate at Global Hunter... American Capital Agency (AGNC) upgraded to Buy from Neutral at Compass Point... Annaly Capital (NLY) upgraded to Buy from Neutral at Compass Point... Aramark (ARMK) upgraded to Outperform at Baird... Bernstein upgrades Yahoo (YHOO), says shares pricing in 'almost' worst case scenario... BreitBurn Energy (BBEP) upgraded to Neutral from Sell at UBS... CAE (CAE) upgraded to Buy from Hold at Desjardins... Capital One (COF) upgraded at Argus... Coca-Cola Enterprises (CCE) upgraded to Outperform from Underperform at CLSA... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... EZchip (EZCH) upgraded to Buy from Hold at Brean Capital... Enzymotec (ENZY) upgraded to Outperform from Market Perform at Wells Fargo... Extra Space Storage (EXR) upgraded on positive catalysts at BMO Capital... Green Plains (GPRE) upgraded to Buy from Neutral at Goldman... Legg Mason (LM) upgraded to Overweight from Equal Weight at Barclays... Lincoln National (LNC) upgraded to Overweight at Morgan Stanley... Merck (MRK) upgraded on improved pipeline outlook at BMO Capital... Microsoft (MSFT) upgraded to Buy from Hold at Stifel... Monster Beverage (MNST) upgraded to Overweight from Equal Weight at Morgan Stanley... National Research (NRCIB) upgraded to Overweight from Equal-Weight at First Analysis... Qlik Technologies (QLIK) upgraded to Buy from Hold at Deutsche Bank... Spectra Energy Partners (SEP) upgraded to Overweight from Neutral at JPMorgan... Yahoo (YHOO) upgraded to Outperform from Market Perform at Bernstein.
08:33 EDTMRKMerck upgraded on improved pipeline outlook at BMO Capital
As noted earlier, BMO Capital upgraded Merck to Outperform from Market Perform. The firm has become more upbeat on the company's pipeline and predicts that upcoming data wil raise the Street's expectations for the company, leading to multiple expansion. The firm is impressed with the company's recent commercial execution and is upbeat on the company's near-term and long-term outlook. Target to $70 from $65.
08:16 EDTPFEPfizer receives approval from ACCC for pending acquisition of Hospira
Pfizer (PFE) announced that the Australian Competition and Consumer Commission has approved the company's pending acquisition of Hospira (HSP) and found no need for remedies. Completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions. Pfizer continus to expect the transaction to close in the second half of 2015.
08:06 EDTBMYBristol-Myers Squibb, Otsuka receive FDA approval for Sprycel labeling
Bristol-Myers Squibb (BMY) and Otsuka (OTSKY) America Pharmaceutical announced that the U.S. Food and Drug Administration has approved an update to the Sprycel product labeling. The labeling now includes five-year efficacy and safety data in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase and seven-year data in CP Ph+ CML patients who are resistant or intolerant to prior therapy, including Gleevec.
08:01 EDTMRKMerck, MD Anderon Cancer Center partner to evaluate Keytruda treatment
Subscribe for More Information
06:29 EDTMRKMerck upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use